Mad Money with Jim Cramer – Nov 12, 2026 (Thur): Key Points & Links｜要点・関連リンク

This page lists the main topics and stocks discussed on Mad Money with Jim Cramer aired on November 12, 2026, with links to CNBC articles, videos, and English transcripts.

2026年11月12日放送の 「Mad Money with Jim Cramer」 で取り上げられた主な話題・銘柄を、CNBCの記事・動画・英文トランスクリプトへのリンクとともに一覧化しています。

(1) Cramer says Jensen Huang betrayed Nvidia shareholders. How to pick up the pieces (https://www.cnbc.com/2026/11/12/nvidia-jensen-huang-exit-cramer.html)

‘Mad Money’ host Jim Cramer recaps the latest news surrounding turmoil at Nvidia and what it means for the company moving forward.

Ticker: NVDA

“Bottom Line: I thought Jensen Huang was a better guy. Did he betray me? No … But did he betray you, the shareholders? Yes. End of story.”

(2) Executive Interview: From Jell-O to Philadelphia cream cheese, Kraft Heinz is putting a new spin on old favorites (https://www.cnbc.com/2026/11/12/kraft-heinz-bets-on-protein-foods-to-revive-sales.html)

• Kraft Heinz CEO Steve Cahillane is betting on new products, including cheesy ramen and protein-packed Jell-O pudding, to revive growth at the packaged food giant.
• Cahillane has invested an additional $700 million in the business and halted plans to split the company.

Ticker: KHC

(3) Know Your IPO: Jim Cramer has three lingering questions about Anthropic ahead of its historic IPO (https://www.cnbc.com/2026/11/12/anthropic-ipo-cramer-pricing-growth-ai-safety.html)

• Jim Cramer identified three lingering questions about Anthropic ahead of its highly anticipated IPO, including the impact of price cuts, future growth opportunities and its focus on AI safety.
• Despite Anthropic’s explosive growth, Cramer remains cautious about buying shares immediately after the IPO.

Ticker: ANT

“Bottom Line: I’m wary of buying Anthropic at a hot open, but hits IPO is one to watch.”

(4) [No Video Clip for non-Club members] Executive Interview: We have studies ongoing in five different tumor types, says Moderna CEO Stéphane Bancel (https://www.cnbc.com/investingclub/video/2026/11/12/we-have-studies-ongoing-in-five-different-tumor-types-says-moderna-ceo-stphane-bancel.html)

Stéphane Bancel, Moderna CEO, joins ‘Mad Money’ host Jim Cramer to talk its partnership with Merck on a cancer treatment, expanding beyond vaccines, clinical trial data, and more.

Ticker: MRNA

(5) Cramer’s lightning round: ‘I’m going to say no to Texas Pacific’ (https://www.cnbc.com/2026/11/12/cramers-lightning-round-im-going-to-say-no-to-texas-pacific.html)

• Commvault Systems: “I saw the CEO on dayside, that’s what we call the watching TV during the daytime, and he was excellent. I thought he did a very good job. I thought he made a good case for his stock, even though it’s up a lot. I think it’s a good call by you.”
• Bright Horizons Family Solutions: “Well, it’s a very expensive stock, but that typically means to me the earnings aren’t going to come through. I don’t want you to mess around with it.”
• Texas Pacific Land Corporation: “You know I’m not really into the oil stocks, and we made a big deal about that stock when it was the right time, and I’m glad we got off that horse. I’m going to say no to Texas Pacific.”

Ticker: CVLT, BFAM, TPL

(6) [No Video Clip for non-Club members] Jim Cramer reflects on meeting fmr. Nvidia CEO Jensen Huang (https://www.cnbc.com/investingclub/video/2026/11/12/jim-cramer-reflects-on-meeting-fmr-nvidia-ceo-jensen-huang.html)

‘Mad Money’ host Jim Cramer reflects on meeting fmr. Nvidia CEO Jensen Huang

Other Stocks Discussed (calls with audience)/ この日の放送で取り上げられたその他の銘柄（視聴者からの電話): Sunoco LP (Texas) (SUN) [I like it. Just own it. If it goes down to 6%, buy more], Whirlpool (WHR) [ I love the product, but maybe they need a kind of a CEO refresh because someone has to pay for that decline.], Lam Research (LRCX) [I think it is a (good entry point). I think it’s come down enough.]

Ref: Links related to this episode /参考: この日の放送に関するその他のサイトへのリンク:

• Podcast at Spotify (Sound /音声）
• Internet Archive（Video & Texts per minute /1分毎のビデオ＆テキスト）

Disclaimer/ 免責事項

****************************